Clinical Trials

The U.S. Department of Defense has awarded $11.4 million to a Boston-based biotherapeutics firm to advance its novel oral prodrug of endogenous allopregananolone, LYT-300, to treat Fragile X-associated Tremor Ataxia syndrome.

Treatment with atogepant at 30 mg and 60 mg reduced mean monthly migraine days over 12 weeks compared with placebo, while showing good safety and tolerability profiles, according to research published in the Lancet Neurology.

Optimal trial participation is an key goal not only for researchers and pharmaceutical companies, but drug development as a whole, but travel requirements can often exclude certain patients with rheumatic diseases before they even begin.

The NIH announced that it has launched phase 2 clinical trials that will evaluate potential treatments for long COVID conditions as part of its Researching COVID to Enhance Recovery, or RECOVER, initiative.

Rates of adverse events were similar in both the pimavanserin group and placebo group.Pimavanserin was well-tolerated and not associated with cognitive decline or motor dysfunction in older adults with Parkinson’s disease and neuropsychiatric symptoms, according to a poster presentation.

BOSTON — Initiating treatment with a high-efficacy therapeutic such as ocrelizumab as early as possible is effective for those with multiple sclerosis, according to a presenter at the American Academy of Neurology annual meeting.

A biotechnology company has announced positive safety and efficacy data from two ongoing phase 1/2a studies as well as an open-label extension study of STK-001 to treat younger individuals with Dravet syndrome.

Cancer clinical trial participation appeared lower among Black and Latinx patients compared with white patients with various cancer types, according to study results published in JAMA Network Open.

In this edition, obesity linked to adverse outcomes among AYAs; pirtobrutinib produces high response rates; CDC study reveals overall increase in pediatric cancer incidence and more.

Genentech announced positive results from its phase 3 OCARINA II clinical trial evaluating Ocrevus as a twice-a-year, 10-minute subcutaneous injection for those with relapsing forms of MS or primary progressive MS.